Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland.

McKeigue, P M; Porter, D; Hollick, R J; Ralston, S H; McAllister, D A; Colhoun, H M

McKeigue, P M; Porter, D; Hollick, R J; Ralston, S H; McAllister, D A; Colhoun, H M.

Affiliation

McKeigue PM; Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Porter D; Public Health Scotland, Glasgow, UK.
Hollick RJ; Department of Rheumatology, Gartnavel General Hospital, Glasgow, UK.
Ralston SH; Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.
McAllister DA; Institute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus, Edinburgh, UK.
Colhoun HM; Public Health Scotland, Glasgow, UK.

Scand J Rheumatol ; 52(4): 412-417, 2023 07.

Article in En | MEDLINE | ID: mdl-35549809

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Rheumatic Diseases / Antirheumatic Agents / COVID-19 Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Scand J Rheumatol Year: 2023 Document type: Article Affiliation country: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google